MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Celldex Therapeutics Inc

Fechado

SetorSaúde

21.98 2.09

Visão Geral

Variação de preço das ações

24h

Atual

Mín

21.66

Máximo

22.3

Indicadores-chave

By Trading Economics

Rendimento

-6.7M

-54M

Vendas

-480K

695K

Margem de lucro

-7,740.432

Funcionários

186

EBITDA

-6.7M

-62M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+146.77% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

4.2M

1.4B

Abertura anterior

19.89

Fecho anterior

21.98

Sentimento de Notícias

By Acuity

50%

50%

115 / 375 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jul. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 15:57 UTC

Conversa de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 de jul. de 2025, 15:49 UTC

Conversa de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Received All Required Authorizations

4 de jul. de 2025, 15:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Agreement Was Announced on Dec. 19

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 de jul. de 2025, 15:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 de jul. de 2025, 14:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 de jul. de 2025, 13:53 UTC

Conversa de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 de jul. de 2025, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 de jul. de 2025, 12:30 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 de jul. de 2025, 12:15 UTC

Conversa de Mercado

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 de jul. de 2025, 12:13 UTC

Conversa de Mercado

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 de jul. de 2025, 12:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

146.77% parte superior

Previsão para 12 meses

Média 54.29 USD  146.77%

Máximo 74 USD

Mínimo 38 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

9

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

115 / 375 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.